Mr. Ian C. Read is Independent Director of KimberlyClark Corporationration Mr. Read was elected Chairman of the Board and Chief Executive Officer in December 2011 and President and Chief Executive Officer in December 2010, of Pfizer, Inc., a drug manufacturer. Mr. Read joined Pfizer in 1978 in its financial organization. He worked in Latin America through 1995, holding positions of increasing responsibility, and was appointed President of the Pfizer International Pharmaceuticals Group, Latin America/Canada in 1996. In 2000, Mr. Read was named Executive Vice President of Europe/Canada and was named a corporate Vice President in 2001. In 2006, he was named Senior Vice President of Pfizer, as well as Group President of its Worldwide Biopharmaceutical Businesses.
Age: 58 Director Since 2007
The company has Return on Asset of 10.2 % which means that on every $100 spent on asset it made $10.2 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 35.62 % implying that it generated $35.62 on every 100 dollars invested.
The company has 7.03 B in debt with debt to equity (D/E) ratio of 1.41 which is OK given its current industry classification. KimberlyClark Corporation has Current Ratio of 0.96 suggesting that it has not enough short term capital to pay financial commitments when the payables are due.
Entity SummaryKimberlyClark Corporationration, together with its subsidiaries, manufactures and markets personal care, consumer tissue, and health care solutions worldwide. KimberlyClark Corporation [KMB] is traded on New York Stock Exchange in USA. It is located in Dallas, TX and employs 58,000 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| KMB NYSE
KimberlyClark Corporation has less than 13.41 (%) percent chance of experiencing financial distress in the next 2 years of operations.
KimberlyClar price boundaries
Promote KimberlyClar and Ian Read